New Opioids: FDA Should Ditch 'Product-Specific Approach,' Science Report Says

FDA-commissioned study recommends agency consider things like off-label use and risks of transition to illicit drugs in opioid approval decisions; opposes restricting market to abuse deterrent formulations.